Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
The company has initiated a Phase I trial of its bivalent RSV and hMPV-targeting vaccine called VXB-241.
The company has initiated a Phase I trial of its bivalent RSV and hMPV-targeting vaccine called VXB-241.
What's Your Reaction?
